Therefore, there is a need to reinforce both the experimental and clinical research in that field, as the application of a proper treatments, such as selective mineralocorticoid receptor antagonists, may prevent the development of complications or reduce the present ones in patients with primary hyperaldosteronism. This evidence concerns the gene NR3C2 and Primary hyperaldosteronism.